MARKET INSIGHTS
Global (R)-2,2‑Dimethyl‑3‑aminobutane (CAS 66228‑31‑7) was valued at USD 28.4 million in 2025 and is projected to rise to USD 52.7 million by 2034, reflecting a 7.3 % CAGR over the forecast period.
(R)-2,2‑Dimethyl‑3‑aminobutane (CAS 66228‑31‑7) Market – View in Detailed Research Report
(R)-2,2‑Dimethyl‑3‑aminobutane is a chiral aliphatic amine whose (R)-configuration and adjacent tert‑butyl group endow it with pronounced steric bulk and enantioselectivity. These attributes make it an indispensable building block for asymmetric synthesis, chiral catalysts, resolving agents and biologically active intermediates.
Demand is sustained by the pharmaceutical sector’s need for enantiopure active pharmaceutical ingredients (APIs), the expanding use of the compound in agrochemical research, and a growing commitment to green chemistry and stereoselective methodologies. Major suppliers such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals and Alfa Aesar supply the compound to research institutions and pharmaceutical manufacturers worldwide.
Top 10 Companies in the (R)-2,2‑Dimethyl‑3‑aminobutane Market
1️⃣ Hairui Industries Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: High‑purity (R)-enantiomers for API development and chiral catalyst synthesis
Hairui Industries leverages its extensive asymmetric synthesis platform to deliver consistent enantiomeric excess (ee) while maintaining competitive pricing. The company’s integrated supply chain reduces lead times for contract manufacturers and supports continuous‑flow processes.
Sustainability & Growth Initiatives: Investment in biocatalytic resolution pathways, reducing solvent consumption by 30 % and aligning with REACH and EPA standards.
- Custom synthesis services for CNS and oncology APIs
- Partnerships with leading CDMOs to scale production
- Focus on energy‑efficient hydrogenation steps
2️⃣ Enamine LLC (Ukraine)
Headquarters: Kyiv, Ukraine
Key Offering: On‑demand synthesis platform for chiral intermediates and specialty reagents
Enamine’s modular synthesis platform enables rapid response to emerging drug pipelines, providing high‑purity intermediates to pharmaceutical giants and academic labs.
Sustainability & Growth Initiatives: Adoption of enzyme‑based resolution processes, lowering carbon footprint and solvent usage.
- Rapid turnaround for custom API intermediates
- Collaborations with biotech firms for targeted delivery
- Integration of continuous‑flow reactors
3️⃣ SynQuest Laboratories, Inc. (USA)
Headquarters: New Jersey, USA
Key Offering: Pharmaceutical‑grade chiral amines and process development services
SynQuest combines advanced synthetic chemistry with robust analytical validation to meet stringent FDA and EMA requirements for chiral purity.
Sustainability & Growth Initiatives: Implementation of green chemistry protocols in its pilot‑scale facilities.
- High‑purity API intermediates for CNS therapeutics
- Process optimization for large‑scale production
- Compliance with GMP and quality assurance standards
4️⃣ Capot Chemical Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: Bulk supply of (R)-dimethyl‑3‑aminobutane for fine‑chemical and agrochemical intermediates
Capot’s strong manufacturing footprint supports high‑volume production while maintaining strict ee controls.
Sustainability & Growth Initiatives: Development of low‑energy hydrogenation processes and waste‑reduction strategies.
- Strategic contracts with large CDMOs
- Expansion of production capacity in 2023 by 20 %
- Continuous improvement of purification workflows
5️⃣ Biosynth AG (Switzerland)
Headquarters: Basel, Switzerland
Key Offering: Specialty chiral intermediates for biopharmaceutical research
Biosynth’s focus on high‑purity grades positions it as a preferred supplier for niche therapeutic programs.
Sustainability & Growth Initiatives: Investment in renewable energy sources for manufacturing plants.
- Custom synthesis for PROTACs and oligonucleotide therapeutics
- Partnerships with leading pharma R&D centers
- Adherence to EU environmental directives
6️⃣ Apollo Scientific Ltd. (UK)
Headquarters: London, UK
Key Offering: High‑purity chiral reagents for fine‑chemical synthesis
Apollo Scientific serves a broad portfolio of academic and industrial clients, emphasizing quality and rapid delivery.
Sustainability & Growth Initiatives: Use of bio‑based solvents in its synthesis processes.
- Supply to UK and European pharmaceutical firms
- Collaboration with universities on catalyst development
- Compliance with UK REACH regulations
7️⃣ Oakwood Products, Inc. (USA)
Headquarters: New Jersey, USA
Key Offering: Pharmaceutical‑grade chiral amines and process engineering services
Oakwood’s integrated approach enables end‑to‑end support for API development projects.
Sustainability & Growth Initiatives: Implementation of energy‑efficient production lines.
- Contract manufacturing for CNS drug candidates
- Process scale‑up for high‑volume production
- Focus on reducing solvent waste
8️⃣ Shanghai Trustin Chemical Co., Ltd. (China)
Headquarters: Shanghai, China
Key Offering: Bulk production of (R)-dimethyl‑3‑aminobutane for fine‑chemical intermediates
Trustin’s manufacturing base supports rapid scaling for emerging drug pipelines.
Sustainability & Growth Initiatives: Adoption of green chemistry principles in its resolution processes.
- Strategic agreements with CDMOs in Asia‑Pacific
- Investment in automated purification systems
- Compliance with Chinese environmental standards
9️⃣ BOC Sciences (USA)
Headquarters: New Jersey, USA
Key Offering: Specialty chiral reagents for pharmaceutical and agrochemical applications
BOC Sciences focuses on delivering high‑purity grades to support advanced synthesis routes.
Sustainability & Growth Initiatives: Integration of renewable energy sources in manufacturing.
- Supply to US and EU pharmaceutical firms
- Collaboration on green catalyst development
- Adherence to FDA and EMA guidelines
1️⃣0️⃣ Taizhou Huangyan Dongsheng Chemical Co., Ltd. (China)
Headquarters: Taizhou, China
Key Offering: High‑purity chiral amines for API synthesis and agrochemical intermediates
Dongsheng’s focus on quality and scalability aligns with the demands of large CDMOs and contract manufacturers.
Sustainability & Growth Initiatives: Development of low‑solvent, high‑yield processes.
- Partnerships with global pharma developers
- Expansion of production capacity in 2024
- Compliance with international environmental regulations
Download FREE Sample Report: (R)-2,2‑Dimethyl‑3‑aminobutane (CAS 66228‑31‑7) Market – View in Detailed Research Report
Get Full Report: (R)-2,2‑Dimethyl‑3‑aminobutane (CAS 66228‑31‑7) Market – View in Detailed Research Report
Market Outlook
With a 7.3 % CAGR, the market is expected to reach USD 52.7 million by 2034. Growth will be supported by increasing investment in chiral drug development, expanding agrochemical applications, and a shift toward sustainable synthesis routes. Regional dynamics indicate Asia‑Pacific as the most active production hub, while North America and Europe continue to drive high‑value API development.
Emerging Trends
- Adoption of biocatalytic resolution technologies, reducing solvent use by up to 30 %.
- Expansion of continuous‑flow manufacturing to cut production costs by 20‑30 %.
- Integration of advanced analytical platforms for rapid ee validation.
- Growing demand for chiral linkers in targeted protein degradation therapies.
Segment Analysis
| Segment Category | Sub‑Segments | Key Insights |
| By Type |
|
Pharmaceutical Grade leads as it meets rigorous purity and enantiomeric excess requirements essential for advanced therapeutics. |
| By Application |
|
Pharmaceutical Intermediates dominate due to the compound’s role as a versatile chiral building block. |
| By End User |
|
Pharmaceutical Manufacturers spearhead demand through in‑house production of novel APIs. |
| By Distribution Channel |
|
Specialty Distributors prevail by offering customized logistics and technical support. |
| By Synthesis Method |
|
Asymmetric Synthesis emerges as the frontrunner for its scalability and cost‑effectiveness. |
Competitive Landscape
The market is concentrated among a few specialized fine‑chemical manufacturers, primarily based in China. These firms benefit from cost‑effective production and expertise in chiral synthesis, accounting for over 70 % of global capacity. Western players operate mainly through custom synthesis services, targeting high‑value markets in Europe and North America. Emerging niche players are pushing sustainable manufacturing, leveraging biocatalytic routes and on‑demand synthesis platforms to capture market share.
Key players include Hairui Industries, Capot Chemical, Enamine, Biosynth, and SynQuest Laboratories. They focus on high‑purity grades, advanced process development, and compliance with stringent regulatory standards.
- Top 10 Companies in the Chromium Oxide Ceramic Materials Market (2026): Market Leaders Driving Innovation - August 4, 2026
- Top 10 Companies in the Immersion Cooling Fluid Materials Market (2026): Market Leaders Driving Thermal Management Innovation - August 4, 2026
- Top 10 Companies in the Thulium Acetate Market (2026): Market Leaders Driving Innovation - August 4, 2026